KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer (2016)
- Authors:
- USP affiliated authors: SILVA, ALFREDO RIBEIRO DA - FMRP ; OLIVEIRA, HARLEY FRANCISCO DE - FMRP ; TIRAPELLI, DANIELA PRETTI DA CUNHA - FMRP ; GARCIA, SERGIO BRITTO - FMRP ; FERES, OMAR - FMRP ; ROCHA, JOSE JOAQUIM RIBEIRO DA - FMRP ; PERIA, FERNANDA MARIS - FMRP
- Unidade: FMRP
- DOI: 10.3233/CBM-160592
- Subjects: BIOMARCADORES; NEOPLASIAS DO COLON; METÁSTASE NEOPLÁSICA; CÉLULAS-TRONCO; MOLÉCULAS DE ADESÃO CELULAR
- Keywords: Colon cancer; KRAS mutation; Cancer stem cell; Biomarker
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Cancer Biomarkers
- ISSN: 1574-0153
- Volume/Número/Paginação/Ano: v. 16, n. 4, p. 513-521, 2016
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
RIBEIRO, Karen Bento et al. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer. Cancer Biomarkers, v. 16, n. 4, p. 513-521, 2016Tradução . . Disponível em: https://doi.org/10.3233/CBM-160592. Acesso em: 19 set. 2024. -
APA
Ribeiro, K. B., Zanetti, J. da S., Ribeiro-Silva, A., Rapatoni, L., Oliveira, H. F. de, Tirapelli, D. P. da C., et al. (2016). KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer. Cancer Biomarkers, 16( 4), 513-521. doi:10.3233/CBM-160592 -
NLM
Ribeiro KB, Zanetti J da S, Ribeiro-Silva A, Rapatoni L, Oliveira HF de, Tirapelli DP da C, Garcia SB, Féres O, Rocha JJR da, Peria FM. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer [Internet]. Cancer Biomarkers. 2016 ; 16( 4): 513-521.[citado 2024 set. 19 ] Available from: https://doi.org/10.3233/CBM-160592 -
Vancouver
Ribeiro KB, Zanetti J da S, Ribeiro-Silva A, Rapatoni L, Oliveira HF de, Tirapelli DP da C, Garcia SB, Féres O, Rocha JJR da, Peria FM. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer [Internet]. Cancer Biomarkers. 2016 ; 16( 4): 513-521.[citado 2024 set. 19 ] Available from: https://doi.org/10.3233/CBM-160592 - CHK2 immunohistochemical expression in colon cancer and its relation with clinicopathological features and outcome in metastatic colon cancer patients
- Clinical-pathological correlation of KRAS mutation status in metastatic colorectal adenocarcinoma
- Transanal endoscopic operation for rectal cancer after neoadjuvant therapy
- Comparative evaluation of oncologic outcomes in colon cancer
- Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors
- CHK2 expression as predictor factor of tumor aggressiveness and shorter survival in metastatic colon cancer patients
- Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer
- Fatigue in patients with colorectal cancer treated with capecitabine and oxaliplatin
- Toxicidade aguda no tratamento neoadjuvante de neoplasia de reto utilizando radioterapia e capecitabina
- Effect of hyperbaric oxygen therapy on the intestinal ischemia reperfusion injury
Informações sobre o DOI: 10.3233/CBM-160592 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
